A phase I randomized, placebo-controlled, double-blind, dose ranging study of the safety, tolerability and immunogenicity of a Clostridium difficile toxoid vaccine, alum adsorbed, in healthy elderly volunteers (greater than or equal to 65 years).

Trial Profile

A phase I randomized, placebo-controlled, double-blind, dose ranging study of the safety, tolerability and immunogenicity of a Clostridium difficile toxoid vaccine, alum adsorbed, in healthy elderly volunteers (greater than or equal to 65 years).

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2012

At a glance

  • Drugs Alum; Clostridium difficile vaccine
  • Indications Clostridium infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi Pasteur Holding
  • Most Recent Events

    • 01 Feb 2012 Results published in the Vaccine.
    • 06 Jan 2009 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
    • 06 Jan 2009 Actual start date (Nov 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top